Home/Filings/4/0001641172-25-005108
4//SEC Filing

Gentry Leesa 4

Accession 0001641172-25-005108

CIK 0001574094other

Filed

Apr 15, 8:00 PM ET

Accepted

Apr 16, 5:18 PM ET

Size

5.9 KB

Accession

0001641172-25-005108

Insider Transaction Report

Form 4
Period: 2025-04-14
Gentry Leesa
Chief Clinical Officer
Transactions
  • Award

    Stock Option

    2025-04-14+26,47726,477 total
    Exercise: $0.84Common Stock (26,477 underlying)
Footnotes (1)
  • [F1]On April 14, 2025, with the approval of the Compensation Committee of the Issuer's Board of Directors, the Reporting Person was granted stock options to purchase up to 26,477 shares of the Issuer's common stock (7,173 shares of which are underlying incentive stock options and 19,304 of which are underlying non-qualified stock options), with such options vesting over four years at a rate of 1/48 per month with no cliff, and with vesting commencing effective January 1, 2025. The options will only become exercisable when there is an effective registration statement covering the shares underlying the options. The options will become fully vested on January 1, 2029, and will expire on April 14, 2035.

Documents

1 file

Issuer

RenovoRx, Inc.

CIK 0001574094

Entity typeother

Related Parties

1
  • filerCIK 0002013097

Filing Metadata

Form type
4
Filed
Apr 15, 8:00 PM ET
Accepted
Apr 16, 5:18 PM ET
Size
5.9 KB